Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axonics, Inc.AXNX · Entity 86004 | Director | November 15, 2024 | November 15, 2024 |
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Director | March 18, 2020 | March 18, 2020 |
| Salona Global Medical Device Corpn/a · Entity 137446 | Director | May 21, 2021 | May 28, 2021 |
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director | May 19, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 19,861 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").
ENDOLOGIX INC /DE/
Report date March 18, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 103,847 |
Reported balance
After 2020-03-18 transaction · row 1
1 source rowRow 1 · 2020-03-18 · Grant · Acquired 103,847 · Balance 103,847 F1: This amount reflects the grant of restricted stock units to the reporting person in connection with her appointment to the board of directors. The restricted stock units will vest as to 25% of the underlying shares of common stock on each anniversary of the grant date such that all of the shares will vest on the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount reflects the grant of restricted stock units to the reporting person in connection with her appointment to the board of directors. The restricted stock units will vest as to 25% of the underlying shares of common stock on each anniversary of the grant date such that all of the shares will vest on the fourth anniversary of the grant date.
Salona Global Medical Device Corp
Report date May 21, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,914 |
Reported balance
Holding disclosure · report date 2021-05-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 114,914 |
TREACE MEDICAL CONCEPTS, INC.
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,949 |
Reported balance
After 2026-05-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 30,000 · Balance 93,949 F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2: Includes 30,000 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.
F2: Includes 30,000 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 20, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-231464 · ownership.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,949 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 30,000 restricted stock units. Read SEC document |
| May 20, 2025 Filed May 21, 2025 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 23,917 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075891 · ownership.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,949 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 20, 2026 or (b) the date of the 2026 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 24,861 restricted stock units. Read SEC document |
| November 15, 2024 Filed Nov 15, 2024 14:00 UTC | Axonics, Inc. AXNX · Entity 86004 | Disposition to issuerCommon Stock | 19,861 | $71.00 | $1,410,131.00 |
DisclosureSEC source: 0001562180-24-007712 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). F1 · price: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 33,260 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0000950170-24-063616 · ownership.xml · derivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,260 Underlying: Common Stock · 33,260 shares Expires 2034-05-21 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 21, 2024, such that the stock option will be fully vested and exercisable on the earlier of (a) May 21, 2025, or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 15,091 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063616 · ownership.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,032 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 21, 2025 or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 18,788 restricted stock units. Read SEC document |
| May 14, 2024 Filed May 14, 2024 22:20 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 19,356 | $5.17 | $100,000.84 |
DisclosureSEC source: 0000950170-24-059856 · ownership.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,941 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.1490 to $5.1698 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 5,585 restricted stock units Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 00:21 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005533 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,861 Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 6,305 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001209191-23-032350 · doc4.xml · derivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,305 Underlying: Common Stock · 6,305 shares Expires 2033-05-23 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 23, 2023, such that the stock option will be fully vested and exercisable on the earlier of (a) May 23, 2024, or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| May 23, 2023 Filed May 26, 2023 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 2,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032350 · doc4.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 23, 2024 or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 5,585 RSUs. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 23:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 19,439 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-22-052526 · doc4.xml · derivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,439 Underlying: Common Stock · 19,439 shares Expires 2032-10-01 F2 · shares: The stock option vests over three years in substantially equal monthly installments with the first vesting to occur on November 1, 2022 such that the stock option will be fully vested and exercisable on October 1, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · derivative.exercise_date: The stock option vests over three years in substantially equal monthly installments with the first vesting to occur on November 1, 2022 such that the stock option will be fully vested and exercisable on October 1, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 23:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 2,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052526 · doc4.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will vest in three equal yearly installments starting October 1, 2023 such that the RSUs will be fully vested on October 1, 2025 subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| August 18, 2022 Filed Aug 23, 2022 00:14 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-006265 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,861 Read SEC document |
| July 05, 2022 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 5,250 | $60.00 | $315,000.00 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · nonDerivative · entry 4 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,761 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| April 01, 2022 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 1,750 | $62.71 | $109,742.50 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · nonDerivative · entry 3 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,011 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:04 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 1,750 | $61.49 | $107,606.98 |
DisclosureSEC source: 0001562180-22-003044 · primarydocument.xml · nonDerivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,594 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.46 to $61.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:04 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 3,500 | $60.00 | $210,000.00 |
DisclosureSEC source: 0001562180-22-003044 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 22, 2021 Filed Nov 3, 2021 01:15 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-006776 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,844 Read SEC document |
| August 05, 2021 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · derivative · entry 6 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option will vest in full on April 8, 2020. Read SEC document |
| August 05, 2021 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,167 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · derivative · entry 5 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires 2029-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest in full on August 22, 2020. Read SEC document |
| August 05, 2021 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 4,167 | $34.10 | $142,094.70 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · nonDerivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Jul 8, 2022 00:20 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 10,000 | $21.04 | $210,400.00 |
DisclosureSEC source: 0001562180-22-005626 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 27, 2020 00:18 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005681 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,583 Read SEC document |
| March 18, 2020 Filed Mar 18, 2020 16:32 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Shares | 103,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000043 · wf-form4_158456353349604.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,847 F1 · shares: This amount reflects the grant of restricted stock units to the reporting person in connection with her appointment to the board of directors. The restricted stock units will vest as to 25% of the underlying shares of common stock on each anniversary of the grant date such that all of the shares will vest on the fourth anniversary of the grant date. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:58 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 4,167 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001562180-19-004491 · primarydocument.xml · derivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2029-08-22 F1 · derivative.exercise_date: The shares subject to the option will vest in full on August 18, 2020. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:58 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004491 · primarydocument.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,083 Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 01:15 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0000899243-19-010422 · doc4.xml · derivative · entry 2 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-08 F1 · derivative.exercise_date: The option becomes exercisable in full on April 8, 2020, provided the reporting person remains in continuous service through such date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 01:15 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-010422 · doc4.xml · nonDerivative · entry 1 Kiernan Jane E · CIK 0001379171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.